OUR SCIENCE
During the metastatic process, tumor cells take on a more invasive profile that helps them spread to other parts of the body. To promote this invasiveness, two well-known changes that occur are the overexpression of matrix metalloproteinases (MMPs) and sialic acids. Higher levels of MMPs are known to aid tumor cells in breaking free from the original tumor, while hypersialylation has been linked to enhancing immune evasion and tumour cell survival.
During the metastatic process, tumor cells take on a more invasive profile that helps them spread to other parts of the body. To promote this invasiveness, two well-known changes that occur are the overexpression of matrix metalloproteinases (MMPs) and sialic acids. Higher levels of MMPs are known to aid tumor cells in breaking free from the original tumor, while hypersialylation has been linked to enhancing immune evasion and tumour cell survival.
Our LPAT technology is designed to specifically target metastatic cancer cells to prevent their adhesion and spread. This is done through a concept known as cancer-activated lectin multivalency, which is used by our drug candidates to target metastatic cancer cells with unmatched specificity. Once metastatic cells are exposed to our treatment, they will consequently lose their metastatic capabilities and be unable to cause tumors. This groundbreaking approach has opened the door for the development of migrastatics that can help cancer survivors be more proactive about living a longer and healthier life.
Our LPAT technology is designed to specifically target metastatic cancer cells to prevent their adhesion and spread. This is done through a concept known as cancer-activated lectin multivalency, which is used by our drug candidates to target metastatic cancer cells with unmatched specificity. Once metastatic cells are exposed to our treatment, they will consequently lose their metastatic capabilities and be unable to cause tumors. This groundbreaking approach has opened the door for the development of migrastatics that can help cancer survivors be more proactive about living a longer and healthier life.
Watch this video to find out more about how our technology works!
[1] Han X, Liu Y, Zhou J, Lai KL, Zhang J, Jai J, Huang J, Lam H, Vong K. (2025) Development of lectin-directed protein aggregation therapy (LPAT) for anti-metastasis applications. Submitted
OUR PIPELINE
CHEMTEIOS is committed to investigating new metastatic cancers where our LPAT technology can be applied as a preventative therapy. Our platform is now streamlined to identify these potential candidates faster for further development or clinical trials.
CHEMTEIOS is committed to investigating new metastatic cancers where our LPAT technology can be applied as a preventative therapy. Our platform is now streamlined to identify these potential candidates faster for further development or clinical trials.
